**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 87674

**Manuscript Type:** CASE REPORT

**Granular cell tumor of the breast: A case report and review of literature**

Yan J. GCTB

Jun Yan

**Jun Yan,** Department of Breast Surgery, The University of Hong Kong - Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China

**Author contributions:** Yan J performed this research, reviewed the articles and wrote the manuscript.

**Corresponding author: Jun Yan, MD, Doctor, Surgeon,** Department of Breast Surgery, The University of Hong Kong - Shenzhen Hospital, No. 1 Haiyuan 1st Road, Futian District, Shenzhen 518000, Guangdong Province, China. yanj@hku-szh.org

**Received:** August 21, 2023

**Revised:** September 26, 2023

**Accepted:** November 13, 2023

**Published online:** November 26, 2023

**Abstract**

BACKGROUND

Granular cell tumor (GCT) of the breast (GCTB) is a rare neoplasm that can exhibit malignant characteristics both clinically and radiologically. This tumor can also coexist and colocalize with breast carcinoma.

CASE SUMMARY

We present a patient with this uncommon tumor and discuss the diagnostic and therapeutic approaches in order to further the knowledge of GCTB and prevent misdiagnosis and overtreatment. The characteristics of the tumor, methods of diagnosis, therapy and postoperative pathological outcomes were analyzed, and relevant literatures of GCTs were reviewed. The patient underwent surgery after core needle biopsy, and the excised neoplasm was sent for pathological examination. Histological analysis revealed nests of cells with abundant pink granular cytoplasm, confirming the diagnosis of GCTB.

CONCLUSION

As manifestations of GCT and malignancy can mimic each other, a careful histological examination is essential before major surgery. Treatment consisting of complete excision with close clinical follow-up is recommended.

**Key Words:** Granular cell tumor; Breast; Neoplasm; Tumor; Literature review; Case report

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Yan J. Granular cell tumor of the breast: A case report and review of literature. *World J Clin Cases* 2023; 11(33): 8044-8049

**URL**: https://www.wjgnet.com/2307-8960/full/v11/i33/8044.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v11.i33.8044

**Core Tip:** Granular cell tumor of the breast is a rare neoplasm that can exhibit malignant characteristics both clinically and radiologically. This tumor can also coexist and colocalize with breast carcinoma. This could result in the potential misdiagnosis of breast carcinoma and overtreatment of patients. We report a patient with this tumor and discuss the methods of diagnosis and treatment. As manifestations of the disease and malignancy can mimic each other, a careful histological examination is essential before major surgery. Complete excision with close clinical follow-up is recommended.

**INTRODUCTION**

Granular cell tumors (GCTs) were first described by Abrikossoff in 1926[1]. These tumors can occur in any part of the body, but are commonly observed in the skin, oral cavity, digestive tract, and subcutaneous tissue. The overall incidence of GCTs in surgical specimens is 0.03%[2]. Breast involvement has been reported in 15% of cases[3]. One to two percent of these lesions can be malignant, with a poor prognosis and few curative options besides surgery[4]. GCT of the breast (GCTB) can mimic breast carcinoma both clinically and radiologically, making it difficult to distinguish from breast malignancies. In order to improve the understanding of GCTB and prevent misdiagnosis and overtreatment, we report a patient with GCTB, who was admitted to our hospital. A brief review of the literature was conducted to further our understanding of this unique disease.

**CASE PRESENTATION**

***Chief complaints***

A 57-year-old woman presented in December 2021 with a lump in her left breast, which had been palpable for approximately 4 mo.

***History of present illness***

The tumor had not significantly increased in size since its discovery.

***History of past illness***

The patient had previously undergone bilateral breast augmentation surgery.

***Personal and family history***

The patient had no family history of breast cancer.

***Physical examination***

Physical examination revealed a spherical, firm, mobile, painless lump measuring approximately 1 cm in diameter and was 5 cm from the nipple in the upper outer quadrant of the left breast. No lymphadenopathy, skin retraction, discharge, thickness or dimpling was observed.

***Laboratory examinations***

No evident abnormalities were detected.

***Imaging examinations***

A standard mammogram showed a 13 mm × 12 mm dense poorly circumscribed tumor in the inner upper quadrant of the left breast. No suspicious calcification or enlarged lymph nodes were found. There were no previous mammograms available for comparison. Ultrasonography demonstrated a hypoechoic nodule, measuring approximately 9.8 mm × 10.6 mm × 9.1 mm at the 10-11 o’clock position close to the margin of left breast gland. The nodule was irregular, with a high depth to width ratio, indistinct, no envelope, the internal echo was non-uniform, a mild posterior shadow was seen without significant peripheral vascularization. No evidence of distant metastasis was found. Magnetic resonance imaging (MRI) revealed a heterogeneous enhanced round mass with a spiculated microlobulated indistinct margin, measuring 9 mm × 8 mm × 9 mm in the left breast at the 10 o’clock position, with a slightly higher signal intensity than adjacent glandular tissue in T1 and T2-weighted sequences. Following contrast administration, heterogeneous enhancement was observed with a slow initial increase in signal intensity followed by a plateau. There were no indications of implant rupture (Figure 1).

**FINAL DIAGNOSIS**

Given the suspicion of breast malignancy, core needle biopsy was performed. Histologic assessment indicated a GCTB.

**TREATMENT**

The patient underwent wide local excision of the tumor.

**OUTCOME AND FOLLOW-UP**

The tumor was identified as a GCT on the basis of its histological characteristics. Six months after surgery, the patient is still doing well.

**DISCUSSION**

GCTs were first described by Abrikossoff in 1926[1]. These tumors can occur in any part of the body. The overall incidence of GCTs in surgical specimens is 0.03%[2]. Breast involvement is observed in 15% of cases[3]. GCTs can occur in all age groups and genders; however, in general, GCTs are almost twice as common in women as in men, predominantly affecting patients in their fourth to sixth decades[2-4]. With a poor prognosis and few curative options besides surgery, one to two percent of these lesions may be cancerous[5]. GCTB mainly occurs in females similar to breast malignancies, but has also been reported in the male population, accounting for 6.6% of all GCTB cases[6]. GCTB frequently resembles malignant neoplasms both clinically and radiologically, making it challenging to distinguish from breast cancers.

Previously, most cases of GCTB were symptomatic; however, with improved breast screening, more asymptomatic cases are being detected. Though some patients have experienced discomfort, pruritis, skin retraction, thickness or dimpling, and reactive lymphadenopathy at presentation, the majority of these tumors are painless, smooth, slow-growing solitary nodules. They can also be multicentric, and even coexist and colocalize with breast carcinoma[1,7]. Therefore, GCTB is difficult to distinguish from carcinoma clinically.

Radiological findings of GCT can be nonspecific in the breast, and are often indistinguishable from those of breast malignancies. They can be small, round, well-circumscribed masses, but also present as indistinct, stellate, sometimes combined with hypodense rims, spiculated with or without calcifications, and skin thickening, associated with the pectoralis on mammography[8].

These tumors on ultrasound are frequently heterogeneous, solid, and poorly defined masses with a posterior shadow and a high depth to width ratio, which often denotes malignancy. Similar to mammography, GCTB on ultrasound has a wide range of properties[9]. The appearance of GCTB on MRI is variable. Benign characteristics such as gradual augmentation, high end intensity, and equal or low signal on T1 and T2 weighted sequences may be present. In addition, malignant features such as fast enhancement, rim enhancement, washout phenomenon, irregular and indistinct lesions may also be observed[10,11]. MRI may be useful in delineating the extent of disease, the presence of aggressive features and contralateral screening; however, no specific features of GCTB have been outlined and GCTB can closely resemble primary breast malignancies[12,13].

To date, only one study has investigated the positron emission tomography/computed tomography features of GCTB. In this case, no evidence of focally enhanced tracer accumulation was revealed. The lesion displayed an average standardized uptake value of 1.8 indicating a benign lesion. Pathological investigation identified this tumor as GCT which infiltrated the subcutaneous and muscular tissue with no mitotic activity. Given the high sensitivity and specificity of positron emission tomography/computed tomography for malignant masses, further study and health economics evaluation are required[12]. Although GCTB are mostly benign, a conclusive pathological diagnosis is essential before surgery to avoid unnecessary radical treatment. Ultrasound guided percutaneous core biopsy of the tumor is well established as the diagnostic procedure for suspicious lesions. While fine needle aspiration cytology smear interpretation has diagnostic challenges including delicate cell membrane and cytoplasm, and insufficient material for immunohistochemical procedures, core biopsy is able to provide specimens that retain their native intracellular architecture to facilitate specific histological diagnosis[14,15]. Pre-operative histological confirmation with core biopsy may contribute to avoiding mastectomy and axillary dissection[16].

Despite the fact that GCTs are often benign, 1%-2% of these lesions can be malignant[5]. Fanburg-Smith *et al*[17] outlined six features including necrosis, increased mitotic count (greater than 2 per 10 high power fields), spindle tumor cells, nuclear pleomorphism, prominent nucleoli, vesicular nuclei, and a high nuclear to cytoplasmic ratio in 1998. If three of these six features are present this is indicative of malignancy, and is atypical if only two features are seen.

It was previously widely accepted that GCTs were derived from Schwann cells of the peripheral nervous system due to the presence S-100 protein[18]. Additionally, GCTs also stained positive for CD68, neuron-specific enolase, vimentin, CD57, CD56, SOX-10 and inhibin[1,19,20]. However, a subset of S100-negative “non-neural” GCTs has been identified[21-25]. The histogenesis of GCT is still debatable at this time.

Complete excision with negative margins and close clinical follow-up is the gold standard treatment strategy for GCTB. Axillary lymph node evaluation, including sentinel lymph node biopsy and lymph node dissection, is only indicated for malignant GCTB[6]. Since the approval of pazopanib for advanced soft tissue sarcomas and metastatic soft tissue sarcomas in the phase III trial, several patients with malignant GCTs have demonstrated a response following treatment with this drug. Establishing the mechanism of action responsible for the disease response *via* limited instances is challenging due to the overexpression of multiple genes by the tumor and various targets of medicines. Clinical trials and appropriate cell lines or mouse models are essential to ascertain the exact mode of action responsible for the tumor response[26-30]. Given the absence of randomized clinical trials on this particular lesion, it is currently believed that there is a limited role for adjuvant therapy, and there is no current standard chemotherapy regimen and radiation therapy for this specific tumor[1].

The prognosis of benign GCT is excellent. However, patients with malignant GCT have a poor prognosis. Malignant GCT has an overall cause-specific survival rate of 74.3% after 5 years and 65.2% after 10 years, respectively. Patients with tumors larger than 5 cm had a worse chance of survival (90.0% *vs* 51.3%, respectively; *P* = 0.02) than patients with tumors smaller than 5 cm. The prognosis was much worse for those who had regional or distant metastases at the time of diagnosis[31].

In this report, we describe a rare breast neoplasm that was radiologically indicative of a malignant tumor but was later determined to be a benign GCTB following extensive local excision. Complete imaging analysis and biopsies could be of significant assistance in making the diagnosis and avoiding invasive procedures. Following a review of the literature, clinical trials and gene research are still required for a deeper knowledge of this rare condition.

**CONCLUSION**

GCTB is a rare disease and can often resemble breast cancer. In the present case, the patient had imaging characteristics of a malignant tumor; however, histologic analysis revealed that the lesion was benign. A thorough imaging evaluation and core needle biopsy are necessary prior to major surgery. Complete excision with negative margins and close clinical follow-up is currently the gold standard treatment strategy for GCTB. Clinical trials and objective molecular data before treatment initiation are needed for deeper knowledge of malignant GCT and the development of effective treatment.

**REFERENCES**

1 **Neelon D**, Lannan F, Childs J. Granular Cell Tumor. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan- [PMID: 33085297]

2 **Lack EE**, Worsham GF, Callihan MD, Crawford BE, Klappenbach S, Rowden G, Chun B. Granular cell tumor: a clinicopathologic study of 110 patients. *J Surg Oncol* 1980; **13**: 301-316 [PMID: 6246310 DOI: 10.1002/jso.2930130405]

3 **Becelli R**, Perugini M, Gasparini G, Cassoni A, Fabiani F. Abrikossoff's tumor. *J Craniofac Surg* 2001; **12**: 78-81 [PMID: 11314193 DOI: 10.1097/00001665-200101000-00013]

4 **Mirza FN**, Tuggle CT, Zogg CK, Mirza HN, Narayan D. Epidemiology of malignant cutaneous granular cell tumors: A US population-based cohort analysis using the Surveillance, Epidemiology, and End Results (SEER) database. *J Am Acad Dermatol* 2018; **78**: 490-497.e1 [PMID: 28989104 DOI: 10.1016/j.jaad.2017.09.062]

5 **Rose B**, Tamvakopoulos GS, Yeung E, Pollock R, Skinner J, Briggs T, Cannon S. Granular cell tumours: a rare entity in the musculoskeletal system. *Sarcoma* 2009; **2009**: 765927 [PMID: 20169099 DOI: 10.1155/2009/765927]

6 **Brown AC**, Audisio RA, Regitnig P. Granular cell tumour of the breast. *Surg Oncol* 2011; **20**: 97-105 [PMID: 20074934 DOI: 10.1016/j.suronc.2009.12.001]

7 **Al-Ahmadie H**, Hasselgren PO, Yassin R, Mutema G. Colocalized granular cell tumor and infiltrating ductal carcinoma of the breast. *Arch Pathol Lab Med* 2002; **126**: 731-733 [PMID: 12033967 DOI: 10.5858/2002-126-0731-CGCTAI]

8 **Leo C**, Briest S, Pilch H, Schütz A, Horn LC, Leinung S. Granular cell tumor of the breast mimicking breast cancer. *Eur J Obstet Gynecol Reprod Biol* 2006; **127**: 268-270 [PMID: 16849031 DOI: 10.1016/j.ejogrb.2006.01.026]

9 **Irshad A**, Pope TL, Ackerman SJ, Panzegrau B. Characterization of sonographic and mammographic features of granular cell tumors of the breast and estimation of their incidence. *J Ultrasound Med* 2008; **27**: 467-475 [PMID: 18314525 DOI: 10.7863/jum.2008.27.3.467]

10 **Iglesias A**, Arias M, Santiago P, Rodríguez M, Mañas J, Saborido C. Benign breast lesions that simulate malignancy: magnetic resonance imaging with radiologic-pathologic correlation. *Curr Probl Diagn Radiol* 2007; **36**: 66-82 [PMID: 17331838 DOI: 10.1067/j.cpradiol.2006.12.001]

11 **Scaranelo AM**, Bukhanov K, Crystal P, Mulligan AM, O'Malley FP. Granular cell tumour of the breast: MRI findings and review of the literature. *Br J Radiol* 2007; **80**: 970-974 [PMID: 17940129 DOI: 10.1259/bjr/95130566]

12 **Hoess C**, Freitag K, Kolben M, Allgayer B, Laemmer-Skarke I, Nathrath WB, Avril N, Roemer W, Schwaiger M, Graeff H. FDG PET evaluation of granular cell tumor of the breast. *J Nucl Med* 1998; **39**: 1398-1401 [PMID: 9708516]

13 **Patel A**, Lefemine V, Yousuf SM, Abou-Samra W. Granular cell tumour of the pectoral muscle mimicking breast cancer. *Cases J* 2008; **1**: 142 [PMID: 18775077 DOI: 10.1186/1757-1626-1-142]

14 **Pieterse AS**, Mahar A, Orell S. Granular cell tumour: a pitfall in FNA cytology of breast lesions. *Pathology* 2004; **36**: 58-62 [PMID: 14757558 DOI: 10.1080/00313020310001646640]

15 **Miller JA**, Karcnik TJ, Karimi S. Granular cell tumor of the breast: definitive diagnosis by sonographically guided percutaneous biopsy. *J Clin Ultrasound* 2000; **28**: 89-93 [PMID: 10641006 DOI: 10.1002/(sici)1097-0096(200002)28:2<89::aid-jcu6>3.0.co;2-n]

16 **Ohnishi H**, Nishihara K, Tamae K, Mitsuyama S, Abe R, Toyoshima S, Abe E. Granular cell tumors of the breast: a report of two cases. *Surg Today* 1996; **26**: 929-932 [PMID: 8931228 DOI: 10.1007/BF00311799]

17 **Fanburg-Smith JC**, Meis-Kindblom JM, Fante R, Kindblom LG. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. *Am J Surg Pathol* 1998; **22**: 779-794 [PMID: 9669341 DOI: 10.1097/00000478-199807000-00001]

18 **Kurtin PJ**, Bonin DM. Immunohistochemical demonstration of the lysosome-associated glycoprotein CD68 (KP-1) in granular cell tumors and schwannomas. *Hum Pathol* 1994; **25**: 1172-1178 [PMID: 7959661 DOI: 10.1016/0046-8177(94)90033-7]

19 **Maiorano E**, Favia G, Napoli A, Resta L, Ricco R, Viale G, Altini M. Cellular heterogeneity of granular cell tumours: a clue to their nature? *J Oral Pathol Med* 2000; **29**: 284-290 [PMID: 10890560 DOI: 10.1034/j.1600-0714.2000.290608.x]

20 **An S**, Jang J, Min K, Kim MS, Park H, Park YS, Kim J, Lee JH, Song HJ, Kim KJ, Yu E, Hong SM. Granular cell tumor of the gastrointestinal tract: histologic and immunohistochemical analysis of 98 cases. *Hum Pathol* 2015; **46**: 813-819 [PMID: 25882927 DOI: 10.1016/j.humpath.2015.02.005]

21 **Lazar AJ**, Fletcher CD. Primitive nonneural granular cell tumors of skin: clinicopathologic analysis of 13 cases. *Am J Surg Pathol* 2005; **29**: 927-934 [PMID: 15958858 DOI: 10.1097/01.pas.0000157294.55796.d3]

22 **Shen Z**, Yao L, Jiang H, Li M, Tang Y. Clinicopathological and immunohistochemical analysis of maxillofacial granular cell tumor. *Hua Xi Kou Qiang Yi Xue Za Zhi* 2023; **41**: 414-420 [PMID: 37474473 DOI: 10.7518/hxkq.2023.2023035]

23 **El Ochi MR**, Essaoudi A, Allaoui M, Abrid JE, Touri S, Moussaoui N, El Ktaibi A, Damiri A, Chahdi H, Oukabli M. Dermal nonneural granular cell tumor: a case report. *J Surg Case Rep* 2022; **2022**: rjac317 [PMID: 35794991 DOI: 10.1093/jscr/rjac317]

24 **Solomon LW**, Velez I. S-100 Negative Granular Cell Tumor of the Oral Cavity. *Head Neck Pathol* 2016; **10**: 367-373 [PMID: 26643916 DOI: 10.1007/s12105-015-0673-6]

25 **Kim BG**, Song JY, Zo S, Im Y, Choi S, Han J, Jeong BH, Kim H. S-100-Negative malignant pulmonary granular cell tumor: A case report. *Respir Med Case Rep* 2020; **29**: 101002 [PMID: 32015959 DOI: 10.1016/j.rmcr.2020.101002]

26 **van der Graaf WT**, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012; **379**: 1879-1886 [PMID: 22595799 DOI: 10.1016/S0140-6736(12)60651-5]

27 **Morita S**, Hiramatsu M, Sugishita M, Gyawali B, Shibata T, Shimokata T, Urakawa H, Mitsuma A, Moritani S, Kubota T, Ichihara S, Ando Y. Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report. *Oncol Lett* 2015; **10**: 972-974 [PMID: 26622607 DOI: 10.3892/ol.2015.3263]

28 **Katiyar V**, Vohra I, Uprety A, Yin W, Gupta S. Recurrent Unresectable Malignant Granular Cell Tumor With Response to Pazopanib. *Cureus* 2020; **12**: e8287 [PMID: 32601562 DOI: 10.7759/cureus.8287]

29 **Conley AP**, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. *J Clin Oncol* 2014; **32**: e107-e110 [PMID: 24550417 DOI: 10.1200/JCO.2012.47.1078]

30 **Wei L**, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. *Cold Spring Harb Mol Case Stud* 2015; **1**: a000380 [PMID: 27148567 DOI: 10.1101/mcs.a000380]

31 **Moten AS**, Zhao H, Wu H, Farma JM. Malignant granular cell tumor: Clinical features and long-term survival. *J Surg Oncol* 2018; **118**: 891-897 [PMID: 30196562 DOI: 10.1002/jso.25227]

**Footnotes**

**Informed consent statement:** The patient provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The author reported no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 21, 2023

**First decision:** August 30, 2023

**Article in press:** November 13, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Mahmoud MZ, Saudi Arabia; Xu JD, China **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Zhao S

**Figure Legends**



**Figure 1** **Imaging photos.** A: Sonography demonstrated a hypoechoic nodule, measuring about 9.8 mm × 10.6 mm × 9.1 mm at the 10-11 o’clock position close to the margin of left breast gland; B: Mammogram showed a 13 mm × 12 mm dense poor-circumscribed mass in inner upper quadrant of the left breast; C: Magnetic resonance imaging revealed a heterogeneous enhancing round-shaped mass with an spiculated microlobulated indistinct margin, measured 9 mm × 8 mm × 9 mm, located at 10 o’clock position of left breast.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**